Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2018

  • ID: 4461747
  • Report
  • 98 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Bayer AG
  • Luye Pharma Group Ltd
  • Ogeda SA
  • Repros Therapeutics Inc
  • MORE
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2018

Summary:

The latest pharmaceutical and Healthcarel and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights:

The latest pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 2, 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Report Coverageproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Bayer AG
  • Luye Pharma Group Ltd
  • Ogeda SA
  • Repros Therapeutics Inc
  • MORE
Introduction

Report Coverage

Uterine Leiomyoma (Uterine Fibroids) - Overview

Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Bayer AG

BioSpecifics Technologies Corp

Kissei Pharmaceutical Co Ltd

Laboratoire HRA Pharma SAS

Luye Pharma Group Ltd

Ogeda SA

Repros Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles

collagenase clostridium histolyticum - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Activate Progesterone Receptor for Uterine Fibroids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elagolix sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLH-2109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relugolix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telapristone acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triptorelin acetate ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulipristal acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vilaprisan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPE-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects

Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products

Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones

Featured News & Press Releases

Dec 01, 2017: EMA starts review of Esmya for uterine fibroids

Nov 09, 2017: Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids

Nov 09, 2017: Takeda Announces Positive Results from its Phase 3 Clinical Trial in Japan Evaluating the Efficacy and Safety of Relugolix in the Treatment of Pain Symptoms Associated with Uterine Fibroids

Oct 31, 2017: Allergan Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterine Fibroids at the American Society for Reproductive Medicine Annual Congress

Oct 23, 2017: Allergan to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids at the American Society for Reproductive Medicine 73rd Annual Congress

Oct 16, 2017: Bayer to present latest clinical data of Vilaprisan at ESG 2017

Oct 10, 2017: Allergan Announces that the FDA Accepts New Drug Application for Ulipristal Acetate for Uterine Fibroids

Oct 03, 2017: Takeda Announces Positive Results from its Phase 3 Confirmatory Clinical Trial in Japan Evaluating the Efficacy and Safety of GnRH Receptor Antagonist Relugolix in Uterine Fibroids

Oct 02, 2017: Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids

Aug 29, 2017: Bayer announces enrollment of first U.S. patient in Phase III trials of vilaprisan in uterine fibroids

Jul 17, 2017: Repros Announces Proellex Development Program Will Remain on Partial Clinical Hold by the FDA

Jul 03, 2017: Bayer starts Phase III study program with Vilaprisan in the treatment of symptomatic uterine fibroids

Jun 07, 2017: ObsEva Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

May 07, 2017: Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Heavy Menstrual Bleeding and Uterine Fibroids at the Annual Meeting of the American Congress of Obstetricians and Gynecologists

Apr 25, 2017: ObsEva Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Laboratoire HRA Pharma SAS, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Ogeda SA, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Repros Therapeutics Inc, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H1 2018

Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Bayer AG
  • BioSpecifics Technologies Corp
  • Kissei Pharmaceutical Co Ltd
  • Laboratoire HRA Pharma SAS
  • Luye Pharma Group Ltd
  • Ogeda SA
  • Repros Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll